menu
    • menu
    [{"orgOrder":0,"company":"Unither Pharmaceuticals","sponsor":"Excelya","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Neurology","graph2":"Phase III","graph3":"Unither Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unither Pharmaceuticals \/ Excelya","highestDevelopmentStatusID":"10","companyTruncated":"Unither Pharmaceuticals \/ Excelya"},{"orgOrder":0,"company":"Unither Pharmaceuticals","sponsor":"Accutest Research Lab I Pvt. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Undisclosed","graph2":"Phase I","graph3":"Unither Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unither Pharmaceuticals \/ Accutest Research Lab I Pvt. Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Unither Pharmaceuticals \/ Accutest Research Lab I Pvt. Ltd"},{"orgOrder":0,"company":"MAXONA Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"MAXONA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAXONA Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MAXONA Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MAXONA Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"MAXONA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAXONA Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MAXONA Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Nefopam Hydrochloride

    Menu

    Nefopam Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MAXONA Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            MAXONA Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maxona Pharmaceuticals Announces MAX-OO1 Phase 1 Clinical Program Results

                            Details : MAX-001 (Nefopam HCl) is a non-opioid, non-NSAID oral therapy, which is currently being evaluated for the treatment of patients with acute and chronic pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2025

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MAXONA Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            MAXONA Pharmaceuticals

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maxona Pharmaceuticals Exits Stealth, Advances MAX-001 First-To-Market Candidate

                            Details : The company's initial focus is on advancing MAX-001 as a safe and highly effective non-opioid option for the treatment of acute and chronic pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 11, 2025

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Unither Pharmaceuticals

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Unither Pharmaceuticals

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Accutest Research Lab I Pvt. Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg)

                            Details : Nefopam HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 22, 2021

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Accutest Research Lab I Pvt. Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Unither Pharmaceuticals

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Unither Pharmaceuticals

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Excelya

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nefopam/Paracetamol Fixed Dose Combination in Acute Pain After Impacted Third Molar Extraction

                            Details : Nefopam HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 10, 2020

                            Lead Product(s) : Nefopam Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Excelya

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth